https://pharmadog.xyz/news/348987 pharmadog en 2026-08-31T21:38:00.000Z Novartis, Bristol Myers pause autoimmune CAR-T trials due to safety concerns https://pharmadog.xyz/news/348563 pharmadog en 2026-08-31T20:00:00.000Z New American Headache Society guidelines highlight expanded migraine prevention options https://pharmadog.xyz/news/348499 pharmadog en 2026-08-31T19:56:17.000Z Trump announces nine voluntary drug pricing agreements with mid-size biotech firms https://pharmadog.xyz/news/348564 pharmadog en 2026-08-31T19:48:44.000Z Trump announces nine new drug pricing agreements to align U.S. prices with peer nations https://pharmadog.xyz/news/348613 pharmadog en 2026-08-31T17:00:00.000Z Crystal Temptations Issues Allergy Alert on Undeclared Milk in Chocolatey Eyeballs https://pharmadog.xyz/news/348337 pharmadog en 2026-08-31T16:44:00.000Z Kofinas Olive Oil voluntarily recalls garlic-infused extra virgin olive oil over unapproved essential oil https://pharmadog.xyz/news/348051 pharmadog en 2026-08-31T16:13:00.000Z FDA clears Takeda and Protagonist's rusfertide (Mimrylo) for polycythemia vera, opening potential $2 billion market https://pharmadog.xyz/news/348011 pharmadog en 2026-08-31T15:56:53.000Z Amgen faces FTC-backed lawsuit over patent-application purchase amid insurer dispute https://pharmadog.xyz/news/347947 pharmadog en 2026-08-31T15:44:09.000Z Industry insiders invited to take Q3 BioPharma Sentiment Survey https://pharmadog.xyz/news/348012 pharmadog en 2026-08-31T15:27:30.000Z GLP-1 drugs push employers to rethink worker health-care costs https://pharmadog.xyz/news/348052 pharmadog en 2026-08-31T15:23:00.000Z Eli Lilly to acquire Merida Biosciences in near-$2.9 billion deal to expand immune-disease pipeline https://pharmadog.xyz/news/347844 pharmadog en 2026-08-31T15:06:50.000Z Biomarin nabs big royalties in achondroplasia patent settlement with Ascendis https://pharmadog.xyz/news/347884 pharmadog en 2026-08-31T14:49:00.000Z Cytokinetics reports Phase 3 success for Myqorzo but shares tumble as investors weigh market impact https://pharmadog.xyz/news/347731 pharmadog en 2026-08-31T14:28:28.000Z Sanofi-backed Electra Therapeutics files for Nasdaq IPO to fund Phase 2/3 immunology program https://pharmadog.xyz/news/347563 pharmadog en 2026-08-31T13:47:00.000Z Eli Lilly to acquire Merida Biosciences for up to $2.875 billion, bolstering its immunology pipeline https://pharmadog.xyz/news/347607 pharmadog en 2026-08-31T13:10:30.000Z Arrowhead’s plozasiran shows favorable safety in severe hypertriglyceridemia late-stage trials https://pharmadog.xyz/news/347479 pharmadog en 2026-08-31T13:03:22.000Z Eli Lilly to acquire Merida Biosciences in up to $2.9 billion deal for precision antibody-degrading therapies https://pharmadog.xyz/news/347499 pharmadog en 2026-08-31T13:03:11.000Z FDA approves Takeda/Protagonist cancer drug Mimrylo as White House readies new drug pricing deals, BioNTech ends colon vaccine trial https://pharmadog.xyz/news/347500 pharmadog en 2026-08-31T12:48:19.000Z Pregnancy hormone explored as possible guide for cardiovascular drug development https://pharmadog.xyz/news/347501 pharmadog en 2026-08-31T12:25:18.000Z Highlights from the European Society of Cardiology meeting and updates on radiopharmaceutical research https://pharmadog.xyz/news/347331 pharmadog en 2026-08-31T11:39:50.000Z Takeda and Protagonist Therapeutics receive FDA approval for rusfertide (Mimrylo) to treat polycythemia vera https://pharmadog.xyz/news/347922 pharmadog en 2026-08-31T11:28:00.000Z Electra Therapeutics files for Nasdaq IPO to fund phase 2/3 immunology and cancer programs https://pharmadog.xyz/news/347795 pharmadog en 2026-08-31T10:47:00.000Z AstraZeneca's oral relaxin agonist shows positive phase 2b results in chronic heart failure https://pharmadog.xyz/news/346967 pharmadog en 2026-08-31T09:00:00.000Z Verily, NVIDIA and NIH launch first multimodal AI model combining EHR and genomics https://pharmadog.xyz/news/346949 pharmadog en 2026-08-31T08:30:00.000Z Radiopharmaceutical experts urge pharma to adopt bolder dosing despite safety concerns https://pharmadog.xyz/news/346947 pharmadog en 2026-08-31T08:30:00.000Z Study reports up to 25% of sampled NFL players had CTE at death, sparking calls for league-wide action https://pharmadog.xyz/news/346948 pharmadog en 2026-08-31T08:30:00.000Z Personalized mRNA melanoma vaccine shows clinical success, reviving optimism for the platform https://pharmadog.xyz/news/347538 pharmadog en 2026-08-31T08:04:00.000Z Eli Lilly to acquire Merida Biosciences for up to $2.88 billion, adding autoimmune antibody-degrading pipeline https://pharmadog.xyz/news/348642 pharmadog en 2026-08-31T07:44:00.000Z Natera partners with Angiex to evaluate Signatera blood test in AGX101 cancer trial https://pharmadog.xyz/news/346267 pharmadog en 2026-08-31T05:01:00.000Z BMS leverages Celgene merger to revive neuroscience pipeline amid delayed readouts https://pharmadog.xyz/news/346119 pharmadog en 2026-08-31T04:04:00.000Z US biotech edge erodes as China overtakes in trials and research, raising security concerns https://pharmadog.xyz/news/344583 pharmadog en 2026-08-30T18:30:18.000Z FDA approves Mimrylo, a weekly injection for polycythemia vera, developed by Protagonist and sold by Takeda https://pharmadog.xyz/news/344298 pharmadog en 2026-08-30T17:29:05.000Z Alnylam defends its heart failure silencers after AstraZeneca's ATTR-CM trial miss https://pharmadog.xyz/news/343987 pharmadog en 2026-08-30T15:40:30.000Z Arrowhead's RNAi drug Redemplo shows safety advantage over Ionis in late-stage triglyceride trials https://pharmadog.xyz/news/342718 pharmadog en 2026-08-30T07:19:28.000Z AstraZeneca’s oral relaxin drug shows partial success in mid-stage heart-failure trial